These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 17210514)
1. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514 [TBL] [Abstract][Full Text] [Related]
2. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Orazi A Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881 [TBL] [Abstract][Full Text] [Related]
3. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Kao JM; McMillan A; Greenberg PL Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988 [TBL] [Abstract][Full Text] [Related]
4. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460 [TBL] [Abstract][Full Text] [Related]
5. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Larson RA Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252 [TBL] [Abstract][Full Text] [Related]
6. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
7. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458 [TBL] [Abstract][Full Text] [Related]
8. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299 [TBL] [Abstract][Full Text] [Related]
10. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Ogasawara T; Yasuyama M; Kawauchi K Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia. Wang H; Wang XQ; Xu XP; Lin GW Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310 [TBL] [Abstract][Full Text] [Related]
12. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution. Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006 [TBL] [Abstract][Full Text] [Related]
13. [Myelodysplastic syndrome--classification, prognosis and therapy]. Cermák J; Michalová K; Vítek A Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420 [TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051 [TBL] [Abstract][Full Text] [Related]
16. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome]. Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904 [TBL] [Abstract][Full Text] [Related]
19. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093 [TBL] [Abstract][Full Text] [Related]
20. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]